Publications by authors named "Luis Fayad"

100Publications

Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.

Lancet Haematol 2020 Mar 3;7(3):e209-e217. Epub 2020 Feb 3.

Center for Personalized Therapy and Clinical Trials Office, UC San Diego Moore's Cancer Center, La Jolla, CA, USA.

View Article and Find Full Text PDF
March 2020

Rosai-Dorfman Disease: The MD Anderson Cancer Center Experience.

Clin Lymphoma Myeloma Leuk 2019 11 4;19(11):709-714. Epub 2019 Jul 4.

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article and Find Full Text PDF
November 2019

Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection.

Blood 2019 06 17;133(26):2800-2802. Epub 2019 May 17.

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article and Find Full Text PDF
June 2019

Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue.

Clin Lymphoma Myeloma Leuk 2019 04 3;19(4):244-250. Epub 2019 Jan 3.

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article and Find Full Text PDF
April 2019

Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?

Ann Hematol 2019 May 8;98(5):1169-1176. Epub 2019 Jan 8.

Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.

View Article and Find Full Text PDF
May 2019

Prevalence of a Histologic Change of Ocular Adnexal Lymphoma in Patients With a History of Lymphoma.

Ophthalmic Plast Reconstr Surg 2019 May/Jun;35(3):243-246

Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, U.S.A.

View Article and Find Full Text PDF
January 2020

Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure.

Leuk Lymphoma 2018 12 26;59(12):2896-2903. Epub 2018 Apr 26.

b Department of Lymphoma/Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article and Find Full Text PDF
December 2018

Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP.

Clin Lymphoma Myeloma Leuk 2018 01 14;18(1):e103-e108. Epub 2017 Nov 14.

Department of Lymphoma and Myeloma, The University of Texas, M.D. Anderson Cancer Center, Houston, TX. Electronic address:

View Article and Find Full Text PDF
January 2018

Rates of Positive Findings on Positron Emission Tomography and Bone Marrow Biopsy in Patients With Ocular Adnexal Lymphoma.

Ophthalmic Plast Reconstr Surg 2017 Sep/Oct;33(5):355-360

*Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, †Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, ‡Department of Ophthalmology and Visual Sciences, The University of Texas Medical Branch, Galveston, Texas, U.S.A.; §Narayana Nethralaya, Narayana Health City, Bangalore, India; ‖Department of Lymphoma and Myeloma, ¶Department of Radiation Oncology, and #Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, U.S.A.

View Article and Find Full Text PDF
September 2017

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.

J Natl Compr Canc Netw 2016 09;14(9):1067-79

From Memorial Sloan Kettering Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; The University of Texas MD Anderson Cancer Center; Massachusetts General Hospital Cancer Center; Stanford Cancer Institute; UCSF Helen Diller Family Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Fox Chase Cancer Center; Huntsman Cancer Institute at the University of Utah; Mayo Clinic Cancer Center; Roswell Park Cancer Institute; University of Michigan Comprehensive Cancer Center; Duke Cancer Institute; Consultant; Dana-Farber/Brigham and Women's Cancer Center; Fred & Pamela Buffett Cancer Center; City of Hope Comprehensive Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; University of Colorado Cancer Center; Vanderbilt-Ingram Cancer Center; UC San Diego Moores Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Alabama at Birmingham Comprehensive Cancer Center; Moffitt Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; St. Jude Children's Research Hospital/University of Tennessee Health Science Center; and National Comprehensive Cancer Network.

View Article and Find Full Text PDF
September 2016

Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement.

Br J Haematol 2017 12 9;179(5):851-854. Epub 2016 Aug 9.

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article and Find Full Text PDF
December 2017

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma.

J Clin Oncol 2016 07 23;34(21):2484-92. Epub 2016 May 23.

Michael Crump, Princess Margaret Cancer Centre, Toronto, Ontario; Kerry J. Savage, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Sirpa Leppä, Helsinki University Hospital Cancer Center, Helsinki, Finland; Luis Fayad, The University of Texas MD Anderson Cancer Center, Houston, TX; Frederick Schnell, Central Georgia Cancer Care, Macon, GA; Robert Rifkin, US Oncology Research Network and Rocky Mountain Cancer Centers, Denver, CO; Lauren Pinter-Brown, University of California at Los Angeles, Santa Monica, CA; Sonali Smith, University of Chicago, Chicago, IL; Eric D. Hsi, Cleveland Clinic, Cleveland, OH; Tuan Nguyen, Peipei Shi, Marjo Hahka-Kemppinen, Don Thornton, and Boris Lin, Eli Lilly and Company, Indianapolis, IN; Brad Kahl, University of Wisconsin, Madison, WI; Thomas Habermann, Mayo Clinic Cancer Research Consortium, Rochester, NY; Je Jung Lee, Chonnam National University Hwasun Hospital, Gwangju, South Korea; Alice Di Rocco, Sapienza University, Rome, Italy; Michinori Ogura, Tokai Central Hospital, Kakamigahara; Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan; Hans Hagberg, Akademiska Sjukhuset, Onkologkliniken, Uppsala, Sweden; Andreas Mackensen, University of Erlangen, Erlangen; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg, Germany; Fritz Offner, University of Gent, Gent, Belgium; and Su-Peng Yeh, China Medical University Hospital, Taichung, Republic of China.

View Article and Find Full Text PDF
July 2016

Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.

Radiology 2016 07 8;280(1):220-9. Epub 2016 Feb 8.

From the Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, and Department of Medical Oncology (R.A.), Stanford University Medical Center, 300 Pasteur Dr, Stanford, CA 94305-5281 (R.M., A.Q.); Department of Radiology, Molecular Imaging Program, Stanford University, Stanford, Calif (R.M.); Departments of Lymphoma/Myeloma (L.F.) and Nuclear Medicine (H.M.), the University of Texas, MD Anderson Cancer Center, Houston, Tex; Oncology/Hematology Section (J.V.) and Department of Radiology (J.H.), University of Nebraska Medical Center, Omaha, Neb; Department of Biostatistics, University of Nebraska Medical Center College of Public Health, Omaha, Neb (J.M.); Department of Nuclear Medicine, University Hospital of Aachen, Aachen, Germany (F.M.); and Department of Radiology and Nuclear Medicine, University of Jordan, Amman, Jordan (M.J.).

View Article and Find Full Text PDF
July 2016

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.

J Clin Oncol 2015 Oct 17;33(30):3467-74. Epub 2015 Aug 17.

Laurie H. Sehn, Centre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia; Tara Baetz, Queen's University, Kingston General Hospital, Kingston; Rena Buckstein, Sunnybrook Health Sciences Center; Michael Crump, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Andre Goy and Luis E. Fayad, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; Fritz C. Offner, Institute of Hematology and Medical Oncology, University of Bologna; Pier Luigi Zinzani, Institute of Hematology "Seràgnoli" University of Bologna, Bologna; Giovanni Martinelli, European Institute of Oncology, Milano; Gianluca Gaidano, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; M. Dolores Caballero, University Hospital of Salamanca, Salamanca, Spain; Ole Gadeberg, Vejle Hospital, Vejle, Denmark; Andrew D. Zelenetz, Memorial Sloan Kettering Cancer Center, New York; Jonathan Friedberg, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY; Branimir Jadkisic, Clinical Hospital Merkur, University of Zagreb, Zagreb, Croatia; Swaminathan Padmanabhan Iyer, Houston Methodist Cancer Center, Weill Cornell Medical College, Houston, TX; Deniz Sahin and Günter Fingerle-Rowson, Roche, Basel, Switzerland; Akiko Chai, Genentech BioOncology, South San Francisco, CA; Oliver Press, Fred Hutchinson Cancer Research Center, Seattle, WA.

View Article and Find Full Text PDF
October 2015

Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma.

Haematologica 2015 Nov 6;100(11):e454-7. Epub 2015 Aug 6.

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Houston, TX, USA.

View Article and Find Full Text PDF
November 2015

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma.

Br J Haematol 2015 Nov 27;171(4):463-70. Epub 2015 Jul 27.

Department of Lymphoma/Myeloma, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA.

View Article and Find Full Text PDF
November 2015

Targeting Wnt pathway in mantle cell lymphoma-initiating cells.

J Hematol Oncol 2015 Jun 6;8:63. Epub 2015 Jun 6.

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.

View Article and Find Full Text PDF
June 2015

Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome.

Am J Hematol 2015 Nov 29;90(11):1091-2. Epub 2015 Apr 29.

Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas.

View Article and Find Full Text PDF
November 2015

Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.

Int J Radiat Oncol Biol Phys 2015 May 5;92(1):122-9. Epub 2015 Mar 5.

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address:

View Article and Find Full Text PDF
May 2015